Memorial Sloan-Kettering Signs Multi-Year Renewal for SciQuest's SelectSite e-Procurement...

Business Editors/Health & Medical Writers

BIOWIRE2K

RESEARCH TRIANGLE PARK, N.C.--(BW HealthWire)--July 22, 2002

Leading research center and hospital realizes significant savings

and efficiencies from using SelectSite during past year

SciQuest,

Inc. (NASDAQ: SQST), a software, information and services company that provides solutions to enhance research operations for pharmaceutical, biotechnology and other research-based organizations, announced today that Memorial Sloan-Kettering, the world's oldest and largest private institution devoted to the prevention, treatment, and cure of cancer, has signed a multi-year license renewal for SciQuest's SelectSite SRA(TM), a comprehensive sourcing and requisitioning application designed specifically for research-intensive organizations.

"Many compelling reasons led us to enter into this multi-year license renewal agreement with SciQuest," said Mark Svenningson, Controller for Memorial Sloan-Kettering. "By utilizing SelectSite's robust catalog, functionality and reporting capabilities, we have identified many savings opportunities. For example, we have identified significant opportunities to develop new contract suppliers and drive additional business to preferred suppliers, giving us the ability to take full advantage of our contracted pricing. We have also realized significant process efficiencies and personnel productivity gains, all of which translate into bottom-line savings. Since SelectSite is a web-based, hosted application, the implementation and maintenance requires very little support from our internal IT organization and has proven to be very reliable. We plan to continue to expand our SelectSite user base, as well as add new suppliers and commodity groups in the coming months."

SelectSite SRA(TM) (Sourcing and Requisitioning Application) is a robust, highly configurable, web-based sourcing, requisitioning and catalog management solution for laboratory products. It is designed for research-intensive organizations seeking to enhance their enterprise procurement software with a researcher-centric "one-stop-shop" application that can reduce off-catalog, off-contract ("maverick" purchases), and non-contract spend. SRA's configurable catalog which consists of over two million products from over 1,000 suppliers combined with the powerful search tools, rich product data, requisition consolidation, reporting, catalog management and integration with other enterprise software systems, contribute to a more efficient and effective product sourcing and requisitioning process.

SelectSite SRA can be implemented quickly and inexpensively and is designed to drive adoption and return-on-investment of enterprise e-procurement software solutions (e.g. Ariba, Oracle, SAP, etc.). Additional SciQuest solutions can also be integrated with SelectSite SRA, including Enterprise Reagent Management (ERM). SciQuest's Professional Services team provides e-commerce consulting, implementation and on-site training programs.

"We are very pleased with the success that a leading organization such as Memorial Sloan-Kettering has experienced with our SelectSite solution," said Stephen J. Wiehe, CEO of SciQuest. "It is our goal to provide research-intensive organizations with solutions that will produce real bottom-line benefits. The renewal agreement with Memorial Sloan-Kettering clearly demonstrates that we are being successful, not only saving our clients money, but also providing them with solutions that enhance business processes and increase productivity."

About SciQuest

SciQuest is a software, information and services company that provides solutions to enhance research operations for pharmaceutical, biotechnology and other research-based organizations. SciQuest is focused on enabling researchers and their organizations to reduce costs, improve efficiencies, increase quality and speed the process of research.

The Company's solutions are specifically designed to help scientists find, acquire and manage the critical research materials they use. These materials include chemical and biological compounds, laboratory supplies, and equipment. SciQuest also helps the suppliers of research materials to better service their customers through enhanced marketing channels and enriched product information.

The Company's solutions can be utilized independently or integrated with leading software, automation equipment and supplier systems to enhance innovation, reduce costs and improve operational effectiveness.

In addition to Memorial Sloan-Kettering, SciQuest customers include many of the world's leading pharmaceutical, biotechnology, chemical, academic and research organizations, such as Abbott Laboratories, Aventis, BayerCropScience, Corixa, Eisai Research Institute, FMC, GlaxoSmithKline, Schering-Plough Research Institute, OSI Pharmaceuticals, Roche, Pfizer and Procter & Gamble. SciQuest is headquartered in Research Triangle Park, N.C., with offices in Philadelphia and London. For more information about SciQuest, please visit www.sciquest.com or call +1-919-659-2100.

SciQuest is a registered trademark of SciQuest, Inc. Enterprise Reagent Manager, Enterprise Substance Manager, ERM Fast Track, ERM Fast Track Plus, ERM for EH&S Management, SelectSite, SelectSite SRA, SelectSite APA, Gene Construction Kit and Gene Inspector are trademarks of SciQuest, Inc.

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties, including all statements regarding SciQuest"s SelectSite SRA(TM). For such statements, the Company claims the protection of the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995. The potential risks and uncertainties associated with these forward-looking statements could cause actual results to differ materially from those presented herein, and the reported results should not be considered as an indication of future performance. Factors that could cause actual results to differ from those contained in the forward-looking statements are discussed in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2002, filed with the Securities and Exchange Commission, under the caption "Factors That May Affect Future Results".